Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 0.50 |
| ▸ | CA1 | P00915 | 14/20 | 0.50 |
| ▸ | CA12 | O43570 | 10/20 | 0.50 |
| ▸ | CA7 | P43166 | 7/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.50 |
| ▸ | CA9 | Q16790 | 11/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 1/20 | 0.44 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 4/20 | 0.40 |
| ▸ | CA6 | P23280 | 4/20 | 0.40 |
| ▸ | CA5A | P35218 | 4/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30232448 | 1.00 | CA2 (0.50) | CA2CA1CA12CA7CA14 | |
| SCHEMBL27675520 | 0.98 | CA2 (0.49) | CA2CA1CA12CA7CA14 | |
| SCHEMBL7993133 | 0.85 | CA2 (0.50) | CA2CA1CA12CA7CA14 | |
| SCHEMBL8353563 | 0.82 | CA2 (0.51) | CA2CA1CA12CA7CA14 | |
| SCHEMBL27886889 | 0.81 | PNMT (0.44) | PNMTLMNA | |
| SCHEMBL996035 | 0.81 | ALDH1A1 (0.34) | CA2CA1CA12CA7CA14 | |
| SCHEMBL25511720 | 0.77 | ALDH1A1 (0.42) | CA2CA1CA12CA7CA14 | |
| Benzenesulfonamide SCHEMBL27317322 | 0.75 | CA2 (0.55) | CA2CA1CA12CA7CA14 | |
| SCHEMBL30232426 | 0.74 | CA1 (0.46) | CA2CA1CA12CA7CA14 | |
| SCHEMBL275807 | 0.71 | CA1 (0.33) | CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705281-A1 | COMPOUNDS FOR TREATING CANCER | Genesis Molecular AI, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024229121-A1 | COMPOUNDS FOR TREATING CANCER | GENESIS THERAPEUTICS, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| US-20230104936-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-20200039945-A1 | Compounds | CTXT PTY LIMITED (AU) | 2020-02-06 | — | — | US | disclosed |
| WO-2018163077-A1 | INDANYL COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS | LUPIN LIMITED (IN) | 2018-09-13 | — | — | WO | disclosed |
| EP-3259253-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | The University of Queensland (AU) | 2017-12-27 | — | — | EP | disclosed |
| CN-107428696-A | Sulfonylureas and related compounds and uses thereof | 昆士兰大学 | 2017-12-01 | — | — | CN | disclosed |
| CN-107266425-A | Pyrazol-1-yl benzene sulfonamides as CCR9 antagonists | 坎莫森特里克斯公司 | 2017-10-20 | — | — | CN | disclosed |
| CN-104520288-B | Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists | 坎莫森特里克斯公司 | 2017-05-17 | — | — | CN | disclosed |
| EP-3083614-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2016-10-26 | — | — | EP | disclosed |
| WO-2016131098-A1 | SULFONYLUREAS AND RELATED COMPOUNDS AND USE OF SAME | THE UNIVERSITY OF QUEENSLAND (AU) | 2016-08-25 | — | — | WO | disclosed |
| WO-2015092713-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-06-25 | — | — | WO | disclosed |
| US-20090118323-A1 | ANTITUMOR BENZOYLSULFONAMIDES | MADER MARY MARGARET | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118323-A1 | ANTITUMOR BENZOYLSULFONAMIDES | HCCS, GLS2, GLS | CA2 1594/4885CA1 428/4885CA12 122/4885 |
| US-20200039945-A1 | Compounds | SLC10A1, ABCB11, PCSK9 | CA2 256/4885CA1 881/4885CA12 365/4885 |
| US-20230104936-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | CA2 294/4885CA1 1974/4885CA12 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.